Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VERDI: Venetoclax + Azacitidine for MRD-Positive AML Pre-alloHCT or Post-Chemotherapy
2024-510648-29-00Phase 3Authorised
- Sponsor
- CETLAM
- Start
- Aug 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of venetoclax and azacitidine in acute myeloid leukemia (AML), sponsored by CETLAM. Primary endpoint: MRD conversion rate after 2 to 4 courses. Planned start Aug 2024; status: authorised.
02
Drugs
venetoclaxazacitidine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2024-510648-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-510648-29-00.